<DOC>
	<DOCNO>NCT00910455</DOCNO>
	<brief_summary>This first study SRX246 human , conduct begin establish safety profile orally administer SRX246 .</brief_summary>
	<brief_title>Study SRX246 Capsules Healthy Adult Volunteers</brief_title>
	<detailed_description>This protocol represent first human study SRX246 , conduct begin establish safety profile , collect human tolerability pharmacokinetic data orally administer SRX246 .</detailed_description>
	<mesh_term>SRX246</mesh_term>
	<criteria>1 . Males nonpregnant , nonlactating female nonchildbearing potential . Female patient either postmenopausal surgically sterile . 2 . Age ≥18 ≤55 year . 3 . Body mass index ( BMI ) 18.5 34.0 kg/m2 , inclusive , total body weight &gt; 50kg ( 110 pound ) . 4 . In good health determine medical history , baseline physical examination , vital sign , clinical laboratory test electrocardiogram ( ECG ) measurement . 5 . Subject willing able sign write informed consent prior receipt study medication begin study procedure . 6 . Subject willing able follow instruction , comply protocol requirement make require study visit . 1 . Pregnant lactating female , female childbearing potential . 2 . Subject positive HIV , hepatitis B surface antigen hepatitis C antibody test screen . 3 . Subject positive urine test drug abuse alcohol screen admission clinic study Day 1 . 4 . Evidence outof range laboratory value screen review , approve document clinically significant Principal Investigator . 5 . Subject rest supine blood pressure outside systolic blood pressure range 90140 mmHg diastolic blood pressure outside range 5090 mmHg two consecutive measurement take 10 minute apart . 6 . Subject rest supine pulse rate great 100 bpm less 50 bpm two consecutive measurement take 10 minute apart . 7 . Subject take alcohol within 48 hour ANY studyrelated activity AND abstain drink alcohol entire duration subject 's study participation . 8 . Subject use tobacco product past 12 month . 9 . A history significant drug allergy systemic allergic disease ( e.g. , urticaria , atopic dermatitis ) . 10 . A general medical psychological condition behavior , include current substance dependence abuse , opinion investigator , might permit subject complete study sign inform consent . 11 . Any clinically significant abnormality screen 12lead ECG ( e.g. , heart block , conduction disorder , ventricular and/or atrial arrhythmia ) . 12 . Any condition clinically significant abnormal finding physical examination , medical history , clinical laboratory result screen , opinion Principal Investigator Physician SubInvestigator , would make subject unsuitable study put additional risk . 13 . Routine PRN consumption medication herbal supplement subject unable unwilling discontinue study . 14 . Inability understand follow study instruction . 15 . Treatment investigational drug within 30 day precede first dose study medication . 16 . Known allergy hypersensitivity investigational study drug/placebo component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>